Epigenetically defined therapeutic targeting in H3.3G34R/V high-grade gliomas
Stefan R Sweha,Chan Chung,Siva Kumar Natarajan,Pooja Panwalkar,Matthew Pun,Amer Ghali,Jill Bayliss,Drew Pratt,Anand Shankar,Visweswaran Ravikumar,Arvind Rao,Marcin Cieslik,Kari Wilder-Romans,Andrew J Scott,Daniel R Wahl,Selin Jessa,Claudia L Kleinman,Nada Jabado,Alan Mackay,Chris Jones,Daniel Martinez,Mariarita Santi,Alexander R Judkins,Viveka Nand Yadav,Tingting Qin,Timothy N Phoenix,Carl J Koschmann,Suzanne J Baker,Arul M Chinnaiyan,Sriram Venneti
DOI: https://doi.org/10.1126/scitranslmed.abf7860
2021-10-13
Abstract:High-grade gliomas with arginine or valine substitutions of the histone H3.3 glycine-34 residue (H3.3G34R/V) carry a dismal prognosis, and current treatments, including radiotherapy and chemotherapy, are not curative. Because H3.3G34R/V mutations reprogram epigenetic modifications, we undertook a comprehensive epigenetic approach using ChIP sequencing and ChromHMM computational analysis to define therapeutic dependencies in H3.3G34R/V gliomas. Our analyses revealed a convergence of epigenetic alterations, including (i) activating epigenetic modifications on histone H3 lysine (K) residues such as H3K36 trimethylation (H3K36me3), H3K27 acetylation (H3K27ac), and H3K4 trimethylation (H3K4me3); (ii) DNA promoter hypomethylation; and (iii) redistribution of repressive histone H3K27 trimethylation (H3K27me3) to intergenic regions at the leukemia inhibitory factor (LIF) locus to drive increased LIF abundance and secretion by H3.3G34R/V cells. LIF activated signal transducer and activator of transcription 3 (STAT3) signaling in an autocrine/paracrine manner to promote survival of H3.3G34R/V glioma cells. Moreover, immunohistochemistry and single-cell RNA sequencing from H3.3G34R/V patient tumors revealed high STAT3 protein and RNA expression, respectively, in tumor cells with both inter- and intratumor heterogeneity. We targeted STAT3 using a blood-brain barrier–penetrable small-molecule inhibitor, WP1066, currently in clinical trials for adult gliomas. WP1066 treatment resulted in H3.3G34R/V tumor cell toxicity in vitro and tumor suppression in preclinical mouse models established with KNS42 cells, SJ-HGGx42-c cells, or in utero electroporation techniques. Our studies identify the LIF/STAT3 pathway as a key epigenetically driven and druggable vulnerability in H3.3G34R/V gliomas. This finding could inform development of targeted, combination therapies for these lethal brain tumors.